温阳健脾化痰汤辅助治疗支气管扩张疗效及对HNP1-3、IL-17变化的研究  

Effect of Wenyang Jianpi Huatan Decoction(温阳健脾化痰汤)in Treatment of Bronchiectasis and Changes of HNP1-3 and IL-17 in Patients

作　　者：马建芳 周媚 李秋 徐文丽 MA Jianfang;ZHOU Mei;LI Qiu;XU Wenli(Zhuji People's Hospital,Zhuji 311800,Zhejiang,China;Zhuji Hospital of Traditional Chinese Medicine,Zhuji 311800,Zhejiang,China)

机构地区：[1]诸暨市人民医院,浙江诸暨311800 [2]诸暨市中医医院,浙江诸暨311800

出　　处：《中华中医药学刊》2024年第1期209-212,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：浙江省自然科学基金基础公益研究计划项目(LGF22H090016)。

摘　　要：目的研究温阳健脾化痰汤辅助治疗支气管扩张的疗效及对患者α-防御素1-3(HNP1-3)、白细胞介素-17(IL-17)的变化影响。方法选取诸暨市人民医院2020年10月—2022年4月收治的支气管扩张缓解期患者86例,采用随机数字法分为两组。对照组给予体位引流、盐酸氨溴索片等常规治疗,汤剂组加用温阳健脾化痰汤治疗,连续治疗4周。分析两组治疗4周后的疗效,检测两组肺功能、相关血清因子及圣乔治呼吸问卷(SGOR)评分、6 min步行距离(6MWT)的差异。结果汤剂组治疗4周后中医证候总有效率(90.70%,39/43)高于对照组(74.42%,32/43),差异有统计学意义(P<0.05)。两组治疗前肺功能指标比较,差异无统计学意义(P>0.05)。汤剂组治疗4周后第1秒用力呼气量(FEV1)[(2.86±0.42)L]、用力肺活量(FVC)[(2.96±0.33)L]、FEV1/FVC(60.47%±6.89%)水平高于对照组(P<0.05)。两组治疗前HNP1-3、白细胞介素-2(IL-2)、白细胞介素-8(IL-8)、IL-17水平比较,差异无统计学意义(P>0.05)。汤剂组治疗4周后除IL-2水平高于对照组外,其他因子水平低于对照组(P<0.05)。两组治疗前SGOR评分、6MWT比较,差异无统计学意义(P>0.05)。汤剂组治疗4周后6MWT[(394.11±70.14)m]长于对照组,SQRQ评分[(12.41±3.65)分]低于对照组(P<0.05)。结论温阳健脾化痰汤辅助治疗支气管扩张可改善肺功能,减轻炎症反应,提高生活质量及运动耐力。Objective To study the effect of Wenyang Jianpi Huatan Decoction(温阳健脾化痰汤)on bronchodilatation and the changes of alpha-defensin 1-3(HNP1-3)and interleukin-17(IL-17)in patients.Methods Eighty-six patients in remission stage of bronchiectasis in Zhuji People's Hospital from October 2020 to April 2022 were selected and randomly divided into two groups.The control group was treated with body position drainage,ambroxol hydrochloride tablets and other conventional treatments,while the decoction group was treated with Wenyang Jianpi Huatan Decoction for 4 consecutive weeks.The therapeutic effects of the two groups after 4 weeks of treatment were analyzed,and the differences in lung function,related serum factors,St.George's Respiratory Questionnaire(SGOR)scores and 6-minute walking distance(6MWT)between the two groups were detected.Results After 4 weeks of treatment,the total effective rate of TCM symptoms in the decoction group was 90.70%(39/43),higher than that in the control group[74.42%(32/43)],with a difference(P<0.05).There was no difference in pulmonary function between the two groups before treatment(P>0.05).The levels of forced expiratory volume(FEV1)[(2.86±0.42)L],forced vital capacity(FVC)[(2.96±0.33)L]and FEV1/FVC[(60.47±6.89)%]in the decoction group at the first second after 4 weeks of treatment were higher than those in the control group(P<0.05).There was no difference in the levels of HNP1-3,interleukin-2(IL-2),interleukin-8(IL-8)or IL-17 between the two groups before treatment(P>0.05).After 4 weeks of treatment,the levels of other factors in the decoction group were lower than those in the control group(P<0.05),except that the level of IL-2 was higher than that in the control group.There was no difference in SGOR score and 6MWT between the two groups before treatment(P>0.05).After 4 weeks of treatment,the 6MWT[(394.11±70.14)m]in the decoction group was longer than that in the control group,and the SQRQ score[(12.41±3.65)point]was lower than that in the control group(P<0.05).Conclusion

关 键 词：温阳健脾化痰汤 支气管扩张 α-防御素1-3 炎症因子 肺功能 

分 类 号：R259.622.2[医药卫生—中西医结合]